Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults

Joon-Young Song, Hee-Jin Cheong, T. F. Tsai, Hyun ah Chang, Min Joo Choi, Ji Ho Jeon, Seong Hee Kang, Eun Ju Jeong, Ji Yun Noh, Woo Joo Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Concomitant administration of influenza and pneumococcal vaccines facilitates their uptake by older adults; however, data on immunogenicity and safety of concomitant administration of adjuvanted trivalent inactivated influenza vaccine (aIIV3) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) have not been reported. Methods: Subjects aged ≥65 years (. N=. 224) were randomized 1:1:1:1 to receive MF59-aIIV3 alone, MF59-aIIV3. +. PPSV23 in contralateral arms, MF59-aIIV3. +. PPSV23 in the same arm or PPSV23 alone (Clinical Trial Number - NCT02225327). Hemagglutination inhibition assay and multiplex opsonophagocytic killing assay were used to compare immunogenicity after single or concomitant vaccination. Results: All groups met immunogenicity criteria for the influenza vaccine in older adults with similar seroconversion rates and geometric mean fold-increases, irrespective of concomitant vaccinations and injection site. For each pneumococcal serotype, opsonic index (OI) increased markedly after the PPSV23 vaccination, irrespective of the concomitant influenza vaccine. All subjects showed an OI. ≥. 8 for serotypes 6B, 18C and 19A post-vaccination, with a suggestion that the ipsilateral concomitant vaccination might be associated with higher OIs for some antigens. Local and systemic adverse events were more common in subjects receiving PPSV23 compared to those receiving aIIV3 alone. Conclusions: No interference was observed with antibody responses to influenza or pneumococcal antigens when aIIV3 and PPSV23 were administered concomitantly.

Original languageEnglish
Pages (from-to)4647-4652
Number of pages6
JournalVaccine
Volume33
Issue number36
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Pneumococcal Vaccines
Influenza Vaccines
influenza
polysaccharides
vaccination
immune response
vaccines
Safety
Vaccination
serotypes
antigens
hemagglutination inhibition test
injection site
seroconversion
crossover interference
Antigens
Inactivated Vaccines
clinical trials
Hemagglutination
MF59 oil emulsion

Keywords

  • Emulsion adjuvant
  • Influenza vaccine
  • Pneumococcal polysaccharide vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. / Song, Joon-Young; Cheong, Hee-Jin; Tsai, T. F.; Chang, Hyun ah; Choi, Min Joo; Jeon, Ji Ho; Kang, Seong Hee; Jeong, Eun Ju; Noh, Ji Yun; Kim, Woo Joo.

In: Vaccine, Vol. 33, No. 36, 01.01.2015, p. 4647-4652.

Research output: Contribution to journalArticle

@article{ea864bf725f14032943346762c22945c,
title = "Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults",
abstract = "Background: Concomitant administration of influenza and pneumococcal vaccines facilitates their uptake by older adults; however, data on immunogenicity and safety of concomitant administration of adjuvanted trivalent inactivated influenza vaccine (aIIV3) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) have not been reported. Methods: Subjects aged ≥65 years (. N=. 224) were randomized 1:1:1:1 to receive MF59-aIIV3 alone, MF59-aIIV3. +. PPSV23 in contralateral arms, MF59-aIIV3. +. PPSV23 in the same arm or PPSV23 alone (Clinical Trial Number - NCT02225327). Hemagglutination inhibition assay and multiplex opsonophagocytic killing assay were used to compare immunogenicity after single or concomitant vaccination. Results: All groups met immunogenicity criteria for the influenza vaccine in older adults with similar seroconversion rates and geometric mean fold-increases, irrespective of concomitant vaccinations and injection site. For each pneumococcal serotype, opsonic index (OI) increased markedly after the PPSV23 vaccination, irrespective of the concomitant influenza vaccine. All subjects showed an OI. ≥. 8 for serotypes 6B, 18C and 19A post-vaccination, with a suggestion that the ipsilateral concomitant vaccination might be associated with higher OIs for some antigens. Local and systemic adverse events were more common in subjects receiving PPSV23 compared to those receiving aIIV3 alone. Conclusions: No interference was observed with antibody responses to influenza or pneumococcal antigens when aIIV3 and PPSV23 were administered concomitantly.",
keywords = "Emulsion adjuvant, Influenza vaccine, Pneumococcal polysaccharide vaccine",
author = "Joon-Young Song and Hee-Jin Cheong and Tsai, {T. F.} and Chang, {Hyun ah} and Choi, {Min Joo} and Jeon, {Ji Ho} and Kang, {Seong Hee} and Jeong, {Eun Ju} and Noh, {Ji Yun} and Kim, {Woo Joo}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2015.05.003",
language = "English",
volume = "33",
pages = "4647--4652",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "36",

}

TY - JOUR

T1 - Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults

AU - Song, Joon-Young

AU - Cheong, Hee-Jin

AU - Tsai, T. F.

AU - Chang, Hyun ah

AU - Choi, Min Joo

AU - Jeon, Ji Ho

AU - Kang, Seong Hee

AU - Jeong, Eun Ju

AU - Noh, Ji Yun

AU - Kim, Woo Joo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Concomitant administration of influenza and pneumococcal vaccines facilitates their uptake by older adults; however, data on immunogenicity and safety of concomitant administration of adjuvanted trivalent inactivated influenza vaccine (aIIV3) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) have not been reported. Methods: Subjects aged ≥65 years (. N=. 224) were randomized 1:1:1:1 to receive MF59-aIIV3 alone, MF59-aIIV3. +. PPSV23 in contralateral arms, MF59-aIIV3. +. PPSV23 in the same arm or PPSV23 alone (Clinical Trial Number - NCT02225327). Hemagglutination inhibition assay and multiplex opsonophagocytic killing assay were used to compare immunogenicity after single or concomitant vaccination. Results: All groups met immunogenicity criteria for the influenza vaccine in older adults with similar seroconversion rates and geometric mean fold-increases, irrespective of concomitant vaccinations and injection site. For each pneumococcal serotype, opsonic index (OI) increased markedly after the PPSV23 vaccination, irrespective of the concomitant influenza vaccine. All subjects showed an OI. ≥. 8 for serotypes 6B, 18C and 19A post-vaccination, with a suggestion that the ipsilateral concomitant vaccination might be associated with higher OIs for some antigens. Local and systemic adverse events were more common in subjects receiving PPSV23 compared to those receiving aIIV3 alone. Conclusions: No interference was observed with antibody responses to influenza or pneumococcal antigens when aIIV3 and PPSV23 were administered concomitantly.

AB - Background: Concomitant administration of influenza and pneumococcal vaccines facilitates their uptake by older adults; however, data on immunogenicity and safety of concomitant administration of adjuvanted trivalent inactivated influenza vaccine (aIIV3) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) have not been reported. Methods: Subjects aged ≥65 years (. N=. 224) were randomized 1:1:1:1 to receive MF59-aIIV3 alone, MF59-aIIV3. +. PPSV23 in contralateral arms, MF59-aIIV3. +. PPSV23 in the same arm or PPSV23 alone (Clinical Trial Number - NCT02225327). Hemagglutination inhibition assay and multiplex opsonophagocytic killing assay were used to compare immunogenicity after single or concomitant vaccination. Results: All groups met immunogenicity criteria for the influenza vaccine in older adults with similar seroconversion rates and geometric mean fold-increases, irrespective of concomitant vaccinations and injection site. For each pneumococcal serotype, opsonic index (OI) increased markedly after the PPSV23 vaccination, irrespective of the concomitant influenza vaccine. All subjects showed an OI. ≥. 8 for serotypes 6B, 18C and 19A post-vaccination, with a suggestion that the ipsilateral concomitant vaccination might be associated with higher OIs for some antigens. Local and systemic adverse events were more common in subjects receiving PPSV23 compared to those receiving aIIV3 alone. Conclusions: No interference was observed with antibody responses to influenza or pneumococcal antigens when aIIV3 and PPSV23 were administered concomitantly.

KW - Emulsion adjuvant

KW - Influenza vaccine

KW - Pneumococcal polysaccharide vaccine

UR - http://www.scopus.com/inward/record.url?scp=84939495272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939495272&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.05.003

DO - 10.1016/j.vaccine.2015.05.003

M3 - Article

C2 - 25980426

AN - SCOPUS:84939495272

VL - 33

SP - 4647

EP - 4652

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 36

ER -